TSLA analyst scorecard · Tesla, Inc.
100 rating actions on TSLA in the last 12 months. Of 164 price targets that resolved, 50 were reached while they stood, 107 were replaced by the same firm first, and 7 fell short at their deadline. Ratings: 48% Buy-type, 36% Hold-type, 16% Sell-type. Consensus target $411, 1% above the last close.
Checked through 2026-10-29 · last close $404.87 (2026-10-29). Rebuilt every morning.
Targets reached while they stood
30.5% 50 of 164
Replaced before the deadline
65.2%
Short at the deadline
4.3%
Ratings vs XLY
9 of 18
Buy / Hold / Sell, 12 mo
48 / 36 / 16%
Consensus target
$411 +1.4%
What the Holds say: 31 Hold-type ratings on TSLA in the last 12 months carried a median target +6% from the price on the day; 23% sat below it.
The 5 upgrades on TSLA came after an average -1.2% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| JPMorgan | Neutral | 2026-10-22 | $430 | 0 | 6 | 6 | 0 of 1 |
| TD Cowen | Buy | 2026-10-22 | $460 | 0 | 3 | 3 | — |
| Canaccord Genuity | Buy | 2026-10-22 | $442 | 2 | 9 | 11 | 1 of 1 |
| Cantor Fitzgerald | Overweight | 2026-10-22 | $485 | 2 | 11 | 13 | 1 of 1 |
| Mizuho | Outperform | 2026-10-22 | $460 | 4 | 8 | 12 | 0 of 1 |
| GLJ Research | Sell | 2026-10-22 | $25 | — | — | 0 | 0 of 1 |
| Wedbush | Outperform | 2026-04-23 | $600 | 2 | 18 | 22 | 1 of 1 |
| RBC Capital | Outperform | 2026-10-22 | $480 | 1 | 7 | 8 | 1 of 1 |
| UBS | Neutral | 2026-10-22 | $425 | 1 | 7 | 8 | 0 of 1 |
| Morgan Stanley | Equal-Weight | 2026-10-22 | $410 | 4 | 3 | 7 | — |
| Truist Securities | Hold | 2026-07-23 | $370 | 5 | 4 | 9 | — |
| Barclays | Overweight | 2026-10-26 | $450 | 4 | 4 | 8 | — |
| StoneX | Buy | 2026-10-22 | $475 | — | — | 0 | — |
| Wells Fargo | Underweight | 2026-07-14 | $130 | 0 | 2 | 2 | 0 of 1 |
| Stifel | Buy | 2026-08-03 | $491 | 2 | 5 | 7 | 1 of 1 |
| Roth Capital | Buy | 2026-07-23 | $505 | — | — | 0 | — |
| Piper Sandler | Overweight | 2026-10-22 | $475 | 3 | 5 | 8 | 1 of 1 |
| Baird | Outperform | 2026-04-06 | $538 | 1 | 5 | 6 | 0 of 1 |
| Needham | Hold | 2026-10-22 | — | — | — | 0 | — |
| Jefferies | Hold | 2026-10-12 | $400 | 1 | 0 | 1 | — |
| Freedom Broker | Hold | 2026-07-02 | $420 | 2 | 0 | 2 | — |
| CLSA | Hold | 2026-10-22 | $400 | 1 | 0 | 1 | — |
| BNP Paribas | Neutral | 2026-10-22 | $420 | — | — | 0 | — |
| Tigress Financial | Buy | 2026-10-08 | $550 | — | — | 0 | — |
| Goldman Sachs | Neutral | 2026-09-16 | $360 | 2 | 2 | 4 | — |
| Citizens | Market Perform | 2026-07-09 | — | — | — | 0 | — |
| Deutsche Bank | Buy | 2025-12-19 | $500 | 2 | 0 | 2 | 1 of 1 |
| Bank of America | Neutral | 2025-10-29 | $471 | 3 | 2 | 5 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor TSLA carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | Barclays | Equal-Weight → Overweight | upgrade | $391.62 | $450 | running to 2027-10-26 | +5.2% |
| 2026-10-22 | UBS | Neutral | maintained | $374.58 | $425 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | CLSA | Underperform → Hold | upgrade | $374.58 | $400 | reached 2026-10-27 | -1.1% |
| 2026-10-22 | Canaccord Genuity | Buy | maintained | $374.58 | $442 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | Morgan Stanley | Equal-Weight | maintained | $374.58 | $410 | running to 2028-04-22 | -1.1% |
| 2026-10-22 | BNP Paribas | Underperform → Neutral | upgrade | $374.58 | $420 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | RBC Capital | Outperform | reiterated | $374.58 | $480 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | JPMorgan | Neutral | maintained | $374.58 | $430 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | TD Cowen | Buy | reiterated | $374.58 | $460 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | Piper Sandler | Overweight | maintained | $374.58 | $475 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | StoneX | Buy | reiterated | $374.58 | $475 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | GLJ Research | Sell | reiterated | $374.58 | $25 | — | -1.1% |
| 2026-10-22 | Mizuho | Outperform | maintained | $374.58 | $460 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | Cantor Fitzgerald | Overweight | reiterated | $374.58 | $485 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | Needham | Hold | reiterated | $374.58 | — | no target | -1.1% |
| 2026-10-20 | Cantor Fitzgerald | Overweight | reiterated | $373.71 | $485 | running to 2027-10-20 | +2.6% |
| 2026-10-15 | GLJ Research | Sell | reiterated | $362.44 | $25 | — | +1.6% |
| 2026-10-12 | Jefferies | Hold | maintained | $378.03 | $400 | reached 2026-10-27 | +3.5% |
| 2026-10-08 | Tigress Financial | Buy | maintained | $375.00 | $550 | running to 2027-10-08 | +1.9% |
| 2026-10-07 | UBS | Neutral | maintained | $377.81 | $391 | within 5% of price when set | +6.7% |
| 2026-09-28 | JPMorgan | Neutral | maintained | $357.45 | $415 | replaced 2026-10-22, new $430 | +2.5% |
| 2026-09-25 | StoneX | Buy | reiterated | $372.11 | $475 | running to 2027-09-25 | +7.6% |
| 2026-09-16 | Goldman Sachs | Neutral | reiterated | $358.08 | $360 | within 5% of price when set | +5.5% |
| 2026-09-04 | GLJ Research | Sell | reiterated | $354.08 | $25 | — | +10.1% |
| 2026-09-03 | StoneX | Buy | reiterated | $376.37 | $475 | running to 2027-09-03 | +15.0% |
| 2026-08-18 | GLJ Research | Sell | reiterated | $336.87 | $25 | — | -11.6% |
| 2026-08-03 | Stifel | Buy | maintained | $322.08 | $491 | running to 2027-08-03 | -18.1% |
| 2026-07-24 | Piper Sandler | Overweight | maintained | $313.03 | $450 | replaced 2026-10-22, new $475 | -16.6% |
| 2026-07-23 | UBS | Neutral | maintained | $319.69 | $385 | replaced 2026-10-07, new $391 | -16.2% |
| 2026-07-23 | JPMorgan | Neutral | maintained | $319.69 | $445 | replaced 2026-09-28, new $415 | -16.2% |
| 2026-07-23 | Morgan Stanley | Equal-Weight | maintained | $319.69 | $400 | replaced 2026-10-22, new $410 | -16.2% |
| 2026-07-23 | Truist Securities | Hold | maintained | $319.69 | $370 | reached 2026-09-03 | -16.2% |
| 2026-07-23 | Mizuho | Outperform | maintained | $319.69 | $450 | replaced 2026-10-22, new $460 | -16.2% |
| 2026-07-23 | TD Cowen | Buy | maintained | $319.69 | $460 | running to 2027-07-23 | -16.2% |
| 2026-07-23 | Canaccord Genuity | Buy | maintained | $319.69 | $410 | replaced 2026-10-22, new $442 | -16.2% |
| 2026-07-23 | RBC Capital | Outperform | reiterated | $319.69 | $500 | replaced 2026-10-22, new $480 | -16.2% |
| 2026-07-23 | Roth Capital | Buy | maintained | $319.69 | $505 | running to 2027-07-23 | -16.2% |
| 2026-07-23 | Cantor Fitzgerald | Overweight | maintained | $319.69 | $485 | running to 2027-07-23 | -16.2% |
| 2026-07-23 | Needham | Hold | reiterated | $319.69 | — | no target | -16.2% |
| 2026-07-21 | GLJ Research | Sell | reiterated | $378.93 | $25 | — | -5.4% |
| 2026-07-14 | Morgan Stanley | Equal-Weight | maintained | $396.18 | $417 | replaced 2026-07-23, new $400 | -2.5% |
| 2026-07-14 | Barclays | Equal-Weight | maintained | $396.18 | $370 | reached 2026-07-20 | -2.5% |
| 2026-07-14 | Wells Fargo | Underweight | maintained | $396.18 | $130 | — | -2.5% |
| 2026-07-13 | Jefferies | Hold | maintained | $394.76 | $400 | within 5% of price when set | -2.9% |
| 2026-07-09 | UBS | Neutral | maintained | $406.55 | $442 | replaced 2026-07-23, new $385 | +2.5% |
| 2026-07-09 | Citizens | Market Perform | initiated | $406.55 | — | no target | +2.5% |
| 2026-07-07 | RBC Capital | Outperform | maintained | $402.90 | $500 | replaced 2026-10-22, new $480 | +3.0% |
| 2026-07-02 | Freedom Broker | Hold | maintained | $393.45 | $420 | running to 2027-07-02 | -7.2% |
| 2026-07-02 | Morgan Stanley | Equal-Weight | maintained | $393.45 | $415 | reached 2026-07-06 | -7.2% |
| 2026-07-02 | Truist Securities | Hold | maintained | $393.45 | $430 | replaced 2026-07-23, new $370 | -7.2% |
| 2026-06-12 | GLJ Research | Sell | reiterated | $406.43 | $25 | — | -8.7% |
| 2026-06-05 | JPMorgan | Underweight → Neutral | upgrade | $391.00 | $475 | replaced 2026-07-23, new $445 | -1.9% |
| 2026-06-04 | TD Cowen | Buy | reiterated | $418.45 | $490 | replaced 2026-07-23, new $460 | +7.5% |
| 2026-04-23 | UBS | Neutral | maintained | $373.72 | $364 | within 5% of price when set | -2.4% |
| 2026-04-23 | Canaccord Genuity | Buy | maintained | $373.72 | $450 | replaced 2026-07-23, new $410 | -2.4% |
| 2026-04-23 | RBC Capital | Outperform | maintained | $373.72 | $475 | replaced 2026-07-07, new $500 | -2.4% |
| 2026-04-23 | TD Cowen | Buy | reiterated | $373.72 | $490 | replaced 2026-07-23, new $460 | -2.4% |
| 2026-04-23 | Cantor Fitzgerald | Overweight | reiterated | $373.72 | $510 | replaced 2026-07-23, new $485 | -2.4% |
| 2026-04-23 | Wedbush | Outperform | reiterated | $373.72 | $600 | running to 2027-04-23 | -2.4% |
| 2026-04-23 | Mizuho | Outperform | maintained | $373.72 | $480 | replaced 2026-07-23, new $450 | -2.4% |
| 2026-04-23 | Needham | Hold | reiterated | $373.72 | — | no target | -2.4% |
| 2026-04-22 | Cantor Fitzgerald | Overweight | reiterated | $387.51 | $510 | replaced 2026-07-23, new $485 | +1.8% |
| 2026-04-21 | Wedbush | Outperform | reiterated | $386.42 | $600 | running to 2027-04-21 | +5.0% |
| 2026-04-15 | TD Cowen | Buy | maintained | $391.95 | $490 | replaced 2026-07-23, new $460 | -0.9% |
| 2026-04-14 | UBS | Sell → Neutral | upgrade | $364.20 | $352 | within 5% of price when set | -6.9% |
| 2026-04-06 | Canaccord Genuity | Buy | maintained | $352.82 | $420 | replaced 2026-04-23, new $450 | -11.1% |
| 2026-04-06 | Baird | Outperform | maintained | $352.82 | $538 | running to 2027-04-06 | -11.1% |
| 2026-03-31 | Canaccord Genuity | Buy | maintained | $371.75 | $420 | replaced 2026-04-23, new $450 | -7.6% |
| 2026-03-30 | GLJ Research | Sell | reiterated | $355.28 | $25 | — | -11.7% |
| 2026-03-27 | Wedbush | Outperform | reiterated | $361.83 | $600 | running to 2027-03-27 | -13.3% |
| 2026-03-12 | GLJ Research | Sell | reiterated | $395.01 | $25 | — | -7.1% |
| 2026-02-19 | GLJ Research | Sell | reiterated | $411.71 | $25 | — | -1.8% |
| 2026-01-30 | JPMorgan | Underweight | maintained | $430.41 | $145 | replaced 2026-06-05, new $475 | -4.3% |
| 2026-01-29 | Morgan Stanley | Equal-Weight | maintained | $416.56 | $415 | within 5% of price when set | -8.3% |
| 2026-01-29 | RBC Capital | Outperform | reiterated | $416.56 | $500 | replaced 2026-04-23, new $475 | -8.3% |
| 2026-01-29 | Wedbush | Outperform | reiterated | $416.56 | $600 | running to 2027-01-29 | -8.3% |
| 2026-01-29 | Cantor Fitzgerald | Overweight | reiterated | $416.56 | $510 | replaced 2026-07-23, new $485 | -8.3% |
| 2026-01-29 | Wells Fargo | Underweight | maintained | $416.56 | $125 | — | -8.3% |
| 2026-01-29 | GLJ Research | Sell | reiterated | $416.56 | $25 | — | -8.3% |
| 2026-01-29 | Mizuho | Outperform | maintained | $416.56 | $540 | replaced 2026-04-23, new $480 | -8.3% |
| 2026-01-29 | Truist Securities | Hold | maintained | $416.56 | $438 | reached 2026-05-11 | -8.3% |
| 2026-01-29 | Needham | Hold | reiterated | $416.56 | — | no target | -8.3% |
| 2026-01-29 | Freedom Broker | Hold | maintained | $416.56 | $440 | reached 2026-05-11 | -8.3% |
| 2026-01-23 | Barclays | Equal-Weight | maintained | $449.06 | $360 | reached 2026-03-30 | -7.5% |
| 2026-01-14 | UBS | Sell | maintained | $439.20 | $307 | replaced 2026-04-14, new $352 | -7.6% |
| 2026-01-12 | Wells Fargo | Underweight | maintained | $448.96 | $130 | — | -2.2% |
| 2026-01-07 | GLJ Research | Sell | maintained | $431.41 | $25 | — | -1.9% |
| 2026-01-02 | Truist Securities | Hold | maintained | $438.07 | $439 | within 5% of price when set | -1.9% |
| 2025-12-30 | Baird | Outperform | reiterated | $454.43 | $548 | replaced 2026-04-06, new $538 | +5.6% |
| 2025-12-23 | Canaccord Genuity | Buy | maintained | $485.56 | $551 | replaced 2026-03-31, new $420 | +24.2% |
| 2025-12-19 | Deutsche Bank | Buy | maintained | $481.20 | $500 | within 5% of price when set | +19.1% |
| 2025-12-19 | Truist Securities | Hold | maintained | $481.20 | $444 | reached 2026-01-02 | +19.1% |
| 2025-12-15 | Wedbush | Outperform | reiterated | $475.31 | $600 | running to 2026-12-15 | +17.6% |
| 2025-12-09 | Piper Sandler | Overweight | maintained | $445.17 | $500 | replaced 2026-07-24, new $450 | +3.6% |
| 2025-12-08 | Morgan Stanley | Overweight → Equal-Weight | downgrade | $439.58 | $425 | within 5% of price when set | +2.3% |
| 2025-11-25 | Mizuho | Outperform | maintained | $419.40 | $475 | reached 2025-12-15 | — |
| 2025-11-17 | Stifel | Buy | maintained | $408.92 | $508 | replaced 2026-08-03, new $491 | — |
| 2025-11-07 | Wedbush | Outperform | reiterated | $429.52 | $600 | running to 2026-11-07 | — |
| 2025-11-05 | Wedbush | Outperform | reiterated | $462.07 | $600 | running to 2026-11-05 | — |
| 2025-10-29 | Bank of America | Neutral | maintained | $461.51 | $471 | within 5% of price when set | — |
Also in Robotics & Physical AI
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.